Bio News
Alzheimer disease agitation indication added, exceeding previous $6 billion estimate Sales force expanded to 630 representatives, with official launch next month
Axsome Therapeutics secured FDA approval for Auvelity as a treatment for Alzheimer disease agitation (ADA), raising the product’s peak sales estimate to $8 billion from the previous range of $2.5 billion to $6 billion. First approved in 2022 as a treatment for major depressive disorder (MDD), Auvelity is the first nonantipsychotic drug for the ADA indication and will compete with Lundbeck and Otsuka’s Rexulti. The company plans to expand its sales force to 630 representatives to target 68,000 health care professionals and officially launch the product for the ADA indication next month.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
